Body mass index as a predictor of fracture risk: a meta-analysis
…, A Odén, H Johanson, O Johnell, P Delmas… - Osteoporosis …, 2005 - Springer
Low body mass index (BMI) is a well-documented risk factor for future fracture. The aim of
this study was to quantify this effect and to explore the association of BMI with fracture risk in …
this study was to quantify this effect and to explore the association of BMI with fracture risk in …
Bone quality—the material and structural basis of bone strength and fragility
E Seeman, PD Delmas - New England journal of medicine, 2006 - Mass Medical Soc
This review discusses advances in knowledge regarding the composition and structure of
bone, the modeling and remodeling of bone, the formation of bone during growth and its …
bone, the modeling and remodeling of bone, the formation of bone during growth and its …
The role of collagen in bone strength
S Viguet-Carrin, P Garnero, PD Delmas - Osteoporosis international, 2006 - Springer
Bone is a complex tissue of which the principal function is to resist mechanical forces and
fractures. Bone strength depends not only on the quantity of bone tissue but also on the quality…
fractures. Bone strength depends not only on the quantity of bone tissue but also on the quality…
[HTML][HTML] Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women
…, J Brun, B Crouzet, S Arnaud, PD Delmas… - New England journal …, 1992 - Mass Medical Soc
… , the number of hip fractures was 43 percent lower (P = 0.043) and the total number of
nonvertebral fractures was 32 percent lower (P = 0.015) among the women treated with vitamin D …
nonvertebral fractures was 32 percent lower (P = 0.015) among the women treated with vitamin D …
[HTML][HTML] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Background A single infusion of intravenous zoledronic acid decreases bone turnover and
improves bone density at 12 months in postmenopausal women with osteoporosis. We …
improves bone density at 12 months in postmenopausal women with osteoporosis. We …
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
…, T Nickelsen, HK Genant, C Christiansen, PD Delmas… - Jama, 1999 - jamanetwork.com
… We report all categories of adverse events for which frequency was different (P<.05) between
the placebo and combined raloxifene groups and for which the incidence was at least 2% …
the placebo and combined raloxifene groups and for which the incidence was at least 2% …
[HTML][HTML] Denosumab for prevention of fractures in postmenopausal women with osteoporosis
…, ES Siris, R Eastell, IR Reid, P Delmas… - … England Journal of …, 2009 - Mass Medical Soc
Background Denosumab is a fully human monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development …
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development …
A meta-analysis of previous fracture and subsequent fracture risk
…, A Odén, P Delmas, J Eisman, S Fujiwara, P Garnero… - Bone, 2004 - Elsevier
Previous fracture is a well-documented risk factor for future fracture. The aim of this study was
to quantify this risk on an international basis and to explore the relationship of this risk with …
to quantify this risk on an international basis and to explore the relationship of this risk with …
Predictive value of BMD for hip and other fractures
…, H Johansson, C De Laet, P Delmas… - Journal of bone and …, 2005 - academic.oup.com
The relationship between BMD and fracture risk was estimated in a meta‐analysis of data
from 12 cohort studies of ∼39,000 men and women. Low hip BMD was an important predictor …
from 12 cohort studies of ∼39,000 men and women. Low hip BMD was an important predictor …
[HTML][HTML] Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
PD Delmas, NH Bjarnason, BH Mitlak… - … England Journal of …, 1997 - Mass Medical Soc
Background Long-term estrogen therapy can reduce the risk of osteoporotic fracture and
cardiovascular disease in postmenopausal women. At present, however, these beneficial …
cardiovascular disease in postmenopausal women. At present, however, these beneficial …